In EGFR-TKI-resistant NSCLC models, U3-1402 was likewise efficacious both when used alone or in combination with an EGFR-TKI, and pretreatment with osimertinib improved the efficacy of U3-1402[121,123,124]. Here, EGFR is linked to non-small cell lung carcinoma.